Incidence of hospitalization or emergency department visit lower for those receiving interferon versus placebo
No Increase Seen in OD Deaths Involving Buprenorphine During COVID-19
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
Fluvoxamine Does Not Improve Time to Sustained Recovery in Mild COVID-19
No difference seen for fluvoxamine, placebo in composite outcome of hospitalization, urgent care visit, emergency department visit, death
VV116 Noninferior to Nirmatrelvir-Ritonavir for COVID-19
Noninferiority established with respect to time to sustained clinical recovery for adults at high risk for progression
Molnupiravir Does Not Reduce COVID-19-Related Hospitalization, Death
No reduction in COVID-19-associated hospitalizations or deaths seen among high-risk, vaccinated adults
Nirmatrelvir Plus Ritonavir Reduces Risks for COVID-19 in Seniors
Reduced risks for hospitalization and death observed for mainly vaccinated outpatients aged 50 years or older with COVID-19
Fewer Buprenorphine Initiation Episodes Seen During Pandemic
Number of active buprenorphine episodes comparable to expected number, with fewer initiations and fewer ending of episodes
Viral Rebound Uncommon After Molnupiravir, Nirmatrelvir-Ritonavir Therapy
Viral rebound uncommon with treatment for patients hospitalized with COVID-19 and not associated with increased mortality
Recommendations Updated for Treatment, Prevention of HIV
Because people with HIV are living longer, management of comorbidities throughout the life span is increasingly important
Paxlovid Safe for Pregnant Patients With COVID-19
However, unexpectedly high rate of cesarean deliveries seen in this cohort